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Abstract
Summary Glucocorticoid use is a risk factor for osteoporosis and fractures. We studied whether women initiating glucocorticoid
treatment also started anti-osteoporotic treatment, according to clinical guidelines. Women with versus without previous fracture
were twice as likely to start anti-osteoporotic treatment within 1 year after initiating glucocorticoid treatment, but the cumulative
incidences were low 9.1% vs. 4.6%, respectively.
Purpose Use of glucocorticoids (GC) is a risk factor for osteoporosis and fractures, and clinical guidelines suggest that preventive
treatment with anti-osteoporotic drugs (AOD) should be considered when starting GC. Women with high risk of osteoporosis
comprise those with previous fractures or a known inflammatory rheumatic disease, for whom the indication of AOD is even
stronger. The purpose of these analyses was to investigate whether women initiating GC treatment also started AOD, especially
those with high risk of osteoporosis.
Methods We used data from the Norwegian Prescription Database to identify all women 55 years and older initiating GC
treatment in Norway during 2010–2016 and to obtain information on use of AOD. Data from the Norwegian Patient Registry
were used to obtain information on previous fractures and diagnoses.
Results Among 105,477 women initiating GC treatment during 2010–2016, 3256 had started AOD and 79,638 had discontinued
GC treatment after 1-year follow-up. Cumulative incidence of starting AOD after 1 year was 9.1% (95%CI: 7.9, 10.4) for women
with vs. 4.6% (95% CI: 4.4%, 4.8%) for women without a previous fracture. Women with rheumatoid arthritis or another
inflammatory rheumatic disease were more likely to start AOD than women with other indications. For the whole cohort, the
probability of starting AOD treatment within 1 year after initiating GC increased on average 3% per year (HR = 1.03, CI: 1.01,
1.05) from 2010 to 2016.
Conclusions Having had a previous fracture or an inflammatory rheumatic disease increased the probability of treatment with
AOD. However, the proportions starting AOD were much lower than clinically indicated.
Keywords Glucocorticoids . Anti-osteoporotic drugs . Osteoporosis . Fracture . Inflammatory rheumatic diseases
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Introduction
Glucocorticoids (GCs) are part of the standard treatment in
many conditions including inflammatory, autoimmune, and
allergic diseases, cancer, and organ transplantations.
Prescription of long-term therapy with GC (3months or more)
has been increasing, and around 1% of the population (1998–
2008) of the UK were treated with GC [1]. Major side effects
include osteoporosis and fractures. Use of GC is the most
common cause of secondary osteoporosis [2, 3], and 30–
40% of all patients treated with GC have radiological evidence
of vertebral fractures [4, 5]. Risk of bone loss and fracture
rises rapidly after GC treatment initiation [6–8]. In addition,
for persons with similar bone mineral density (BMD), the risk
of vertebral fractures is larger for GC users than for nonusers
[9], indicating an additional effect on bone quality. The harm-
ful effects on bone are dose-dependent, but no safe dose limit
has been established [8].
According to both older and newer guidelines in Europe
and the USA, the threshold for starting preventive treatment
with anti-osteoporotic drugs (AOD) after initiation of GC
medication should be low. This applies especially to high-
risk patients (e.g., those with a history of low-energy fracture)
or if GC therapy is intended to last for more than 3 months
[10–12]. These recommendations were also implemented in
the guidelines from the Norwegian Society of Rheumatology
in 2015 [13]. However, overall use of AOD in Norway is
lower than in other European countries [14–16]: in a
Norwegian study, only 22.5% of women already receiving
GC were treated with AOD during the first year after a fore-
arm fracture [15]. Another Norwegian study found that use of
AOD was highest in areas with the historically lowest inci-
dence of osteoporotic fractures [17]. This indicates that,
among those at highest risk of suffering a fracture, a subopti-
mal proportion receives anti-osteoporotic treatment.
GCs have for several decades been an important part of
therapy in several inflammatory rheumatic diseases; patients
with rheumatoid arthritis (RA), for example, may receive GC
over many years [18, 19]. Treatment with GC may have a
bone protective effect in highly inflammatory states [20],
and the majority of newly diagnosed RA patients are treated
with GC in the early stages to achieve rapid disease remission
[21]. Both the disease and the treatment with GC are poten-
tially harmful to the bone, and RA is the only medical condi-
tion considered to be a separate risk factor in the fracture risk
assessment tool FRAX® [22]. There has been increasing em-
phasis on limiting use of GC to short periods and in moderate
doses [23], but studies have not found a reduced use of GC in
patients with RA [1, 19]. Another inflammatory rheumatic
disease, giant cell arteritis (GCA), requires high doses and
often long-term treatment with GC due to risk of serious com-
plications including blindness if not adequately treated. Until
recently, there has been no alternative treatment to GC for this
condition, and in Norway, GC is still preferred due to low
economical costs. Polymyalgia rheumatica (PMR), despite
being commonly regarded as a disease with low morbidity,
is one of the most common indications for starting GC [1].
Because PMR patients are often older than patients with RA at
disease onset, they have a higher prevalence of previous frac-
tures [24]. In addition, many of them sustain new fractures
during GC treatment [24]. Even though the risk of osteoporo-
sis and fractures due to long time GC therapy is substantial,
the attentiveness to osteoporosis prophylaxis has been low
[25].
Although treatment guidelines are clear and most physi-
cians are aware of the detrimental effect of GC on bone, the
degree to which these guidelines are adhered to in clinical
practice is not clear. Thus, our primary aim was to examine
the initiation of osteoporosis prophylaxis with AOD inwomen
starting treatment with oral GC. We further investigated
whether high-risk groups, i.e., women with a history of frac-
ture or a rheumatic inflammatory disease, were more likely to
receive AOD after starting GC. Finally, we examined changes
in the prescribing rates of AOD at GC initiation from 2010 to
2016.
Methods
Study design and study population
This was a nationwide cohort study using data from the
National Registry of Norway [26], the Norwegian
Prescription Database (NorPD) [27, 28], the Norwegian
Patient Registry (NPR) [29], the Norwegian Cause of Death
Registry [30], and the Norwegian Education Database [31]. In
Norway, every resident is assigned a unique identification
number which enables exact linkage of each individual’s data
from various registries. Government-funded hospitals and
specialty clinics are required to report to the NPR, and diag-
noses from all in- and outpatient hospital encounters have
been recorded since 2008 [32]. The Norwegian Cause of
Death Registry provides information on deaths and has high
completeness [33]. The NorPD contains information on all
prescription dispensings at outpatient pharmacies, ordered
by physicians in both primary and specialist health care.
The source population consisted of 1,004,067 Norwegian
women aged 55 years or older registered in the National
Registry of Norway during 2010–2016. The study population
consisted of all women initiating GC treatment (GC naïve),
defined as having at least one GC dispensing from an outpa-
tient pharmacy during the study period and with no dispens-
ings during a 5-year look-back period. Prednisolone is the
most commonly used GC outpatient treatment regimen, while
prednisone is not a registered drug in Norway. Only systemic
GC was studied (Table S1/Supplementary).
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Only AOD naïve women initiating GC were included, ex-
cluding prevalent AOD users at the onset of GC treatment (5-
year look-back) (Fig. 1). We expected a high proportion of
women 85 years or older to live in nursing homes, and med-
ication administered there are not registered in the NorPD;
thus, women aged 85+ years at GC initiation treatment were
excluded. Finally, women initiating GC treatment due to pal-
liative care in cancer were excluded (identified through reim-
bursement codes, described below). The study population thus
included 105,477 AOD naïve women (55–84 years) starting
GC treatment, with follow-up through 2017.
Time at risk
A patient was considered at risk of starting AOD treatment
from the date of the first GC dispensing until discontinuation
of GC treatment, the latter defined as a period without a new
GC dispensing of 180 days or longer (grace period) beyond
what was expected based on the days supplied in the last-
recorded GC dispensing. Impact of the chosen grace period
was examined in a sensitivity analysis where the grace period
was changed to 90 days.
Exposure
Fracture diagnoses for the hip, femur, ulna, radius, spine, pel-
vis, and humerus were obtained in the 2-year pre-GC baseline
period and used as the exposure in the analyses (Table S2/
Supplementary).
In Norway, GC treatment for certain diagnoses is reim-
bursed through governmental funding (i.e., at no, or low, cost
for the patient). Such reimbursement diagnosis codes were
used to identify the underlying disease (“GC indications,”
Table S3). Reimbursement diagnosis code belonging to the
first GC dispensing were categorized into four indication
groups and used as exposure: “rheumatoid arthritis,” “other
inflammatory rheumatic disease,” “other indications,” and
“indication not known” (supplementary Table S3). Women
without reimbursement at first GC dispensing (60%) or with
reimbursement but with missing reimbursement diagnosis
GC=glucocorticoid; AOD=anti-osteoporotic drugs
N=151,531
with at least one dispensaon 
of GC from a pharmacy
Excluding 852,536 women not 
iniang GC treatment in 
2010-2016
Source populaon: 








Excluding 2,022 women with 
palliave care indicaon when 
iniang GC treatment
N=137,197
Excluding 14,334 women with 
prevalent (5 year wash-out) 
AOD use
(already started AOD before 
iniaon of GC) 
N=135,175
Excluding 29,698 women age 
85+ when iniang GC
Fig. 1 Norwegian women 55–
84 years old initiating
glucocorticoid (GC) treatment
during 2010–2016. Flowchart of
study population with inclusion
and exclusion criteria
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code (5%) were categorized according to the ICD-10 diagno-
ses that could be indications for GC treatment, obtained from
the NPR during the 2-year baseline period. In case of more
than one potential indication, the most recent diagnosis rela-
tive to the first GC dispensing was used. The category “other
indications” includes chronic obstructive lung disease, asth-
ma, sarcoidosis, dermatitis, and ulcerative colitis (Table S4/
Supplementary).
Outcome
The time from the first GC dispensing until the first dispensing
of AOD was used as the outcome in the analyses, treating
discontinuation of the GC treatment as a censoring event,
death as a competing event (cumulative incidence) or censor-
ing event (Cox regression), and emigration or end of the study
period (31 December 2017), whichever came first, as censor-
ing events. AOD included in the study are listed in Table S1
(Supplementary).
Covariates
Diagnoses describing comorbidity were obtained according to
the Romano modification of the Charlson comorbidity index
(CCI) [29, 34]. This modification differs from the original
CCI in that it includes dementia but excludes HIV. It further
includes inflammatory rheumatic disease categories (connec-
tive tissue disease) such as rheumatoid arthritis, GCA, system-
ic lupus erythematosus (SLE), dermatopolymyositis, systemic
sclerosis, and PMR. Information on relevant drug use (except
GC and AOD) was collected for each woman in the 2-year
baseline period preceding GC initiation. We did not adjust for
CCI in the final analysis, as this only altered the associations
slightly.
Education, age, and year at GC initiation were all adjusted
for in the Cox regression analyses. Information on highest
achieved education was obtained from the Norwegian
Education Database [35] and categorized into basic (compul-
sory), secondary (high school/vocational education), or tertia-
ry (college or university).
Statistical analyses
Distributions of continuous variables were reported as me-
dians and interquartile ranges; categorical variables were sum-
marized using counts and percentages. Cumulative incidence
of initiating AOD was calculated using the Aalen-Johansen
method for competing risk, treating death as a competing
event, stratified by having a history of fracture, among all
women initiating GC and among women with known indica-
tion for GC treatment, stratified by GC indication, and strati-
fied by Defined Daily Dose (DDD) of GC initially given (<
90 DDD and > = 90 DDD). Due to the low number of patients
at risk after 5-year follow-up, we used 5 years as the maximum
follow-up when calculating cumulative incidence.
Cox regression was used to estimate associations (HRs)
between women with versus without a previous fracture and
initiation of AOD at 1-year follow-up, stratified by GC indi-
cation and by DDD of GC initially given. In this analysis,
death and termination of GC treatment were treated as censor-
ing events. Analyses were adjusted for age at the index date
(5-year age groups) and year initiating GC (linear term) and
education. Due to few GC naïve patients with a previous frac-
ture starting AOD treatment after 1-year GC treatment, we
only present hazard ratios for fracture versus no previous frac-
ture for starting AODwithin 1 year after GC treatment and not
for longer follow-up periods.
Age-standardized incidence rates of initiating AOD within
1 year from start of GC treatment were calculated using the
direct method with 5-year age intervals using all women 55–
84 years in Norway as the standard, treating discontinuation of
GC treatment, death, and emigration as censoring events.
We calculated time trends of initiating AOD within 1 year
of starting GC treatment, calculating hazard ratios using Cox
regression, adjusting for age and education. We tested for
possible interactions between time trend and GC indication
and with previous fracture.
In all analyses, 95% confidence intervals (CIs) were calcu-
lated, and all analyses were conducted using R.
Ethics
The study was approved by the Regional Committee for
Medical and Health Research Ethics and by the Norwegian
Data Protection Authority.
Results
Baseline characteristics of the study population are presented
according to a 2-year pre-baseline history of fracture
(Table 1). About 3.7% of the study population had a fracture
before initiation of GC, and the women in this group were
older, and they had a higher comorbidity in most disease cat-
egories and a higher CCI score than women without fracture.
Use of immunosuppressant medication other than GC was
slightly higher for the fracture group. Women without a pre-
vious fracture had higher educational level than women with a
fracture. While 3.0% in the total cohort had a diagnosis of
rheumatoid arthritis registered in the NPR, 8.6% in the no
fracture group and 8.8% in the previous fracture group had a
rheumatoid arthritis reimbursement code from the primary or
the specialist health care at the first GC dispensing.
Women with and without previous fracture had similar
amount of reimbursement at their first GC dispensing, 41%
versus 37%, respectively. Among those with reimbursement,
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the majority had a known reimbursement code (known indi-
cation) (Table 1).
A total of 4504 women started AOD during follow-up
(minimum 1 year and maximum almost 8 years), where
3256women had started AOD and 79,638were censored after
1-year follow-up. Among women with rheumatoid arthritis or
other inflammatory rheumatic disease, 50% had discontinued
GC treatment after 1-year follow-up versus 80% among wom-
en with other GC indications and 86% with no known GC
indication. Among women who started AOD treatment (and
without a GC treatment gap of more than 180 days), median
time between the first GC and the first AOD prescription
dispensation was 592 days (interquartile range (IQR): 203,
1209) for women without a previous fracture and 417 days
(IQR: 149, 944) among women with a previous fracture.
Cumulative incidence of starting AOD was higher at any
time point among women with versus without a previous frac-
ture. This was true both for womenwith known GC indication
and among all women (Fig. 2). Further, cumulative incidence
of starting AOD at 1-year follow-up was slightly higher
among women with a known GC indication compared with
all women, both for women with previous fracture and no
fracture, and this difference persisted through the 5-year fol-
low-up (Fig. 2). Among all women initiating GC, the cumu-
lative incidence of starting AODwithin 1 year was 9.1% (95%
CI: 7.9, 10.4) among women with fracture versus 4.6% (95%
CI: 4.4%, 4.8%) among those without fracture (Fig. 2). After
5-year follow-up, cumulative incidence was 30.2% (95% CI:
23.8%, 36.5%) among women with fracture versus 23.2 (95%
CI: 21.9%, 24.5%) among women without.
Among women with known indication for GC treatment,
the cumulative incidences at 1-year follow-up were 11.8%
(95% CI: 10.0, 13.5) for women with a fracture and 7.1%
(95% CI: 6.8, 7.4) without fracture (Fig. 2).
Cumulative incidences of receiving AOD within 1 year after
initiation of GC treatment among women with rheumatoid ar-
thritis and other inflammatory rheumatic diseases were 10.1%
(95% CI: 9,5, 10.8) and 13.3% (95% CI: 12.5, 14.1), respective-
ly. This was 2–3 times higher (and decreasing over time) than for
women with other indications and for indication not known (cu-
mulative incidence 3.6 (95% CI: 3.2, 3.9) and 2.4 (95% CI: 2.2,
2.7), respectively) (Fig. 3, left). After 5-year follow-up, the cu-
mulative incidences were 30.6% for rheumatoid arthritis, 30.4%
for other inflammatory rheumatic disease, 21.6% for other indi-
cations, and 18.8% for indication not known.
Cumulative incidence of receiving AODwithin 1 year after
initiation of GC treatment was higher among women receiv-
ing an initial dose of GC of more than 90 DDD for any indi-
cation, and this difference was highest among women with
other inflammatory rheumatic diseases (Fig.3, right). A ma-
jority of women received an initial dose of less than 90 DDD,
and a high proportion of these continuedGC treatment beyond
1 year.
The higher 1-year probability of receiving AOD in the
fracture group persisted after adjusting for baseline covariates
(age, education, and year of initiation of GC), with a HR of 2.0
(95% CI: 1.8, 2.3) (Table 2). Among women with rheumatoid
arthritis or another inflammatory rheumatic disease as indica-
tion for GC treatment, the probability of starting AOD within
1 year was 1.5–1.6 times higher when having had a previous
fracture versus no fracture (Table 2). Among women with
other known indications for GC treatment and for womenwith
no known indication for GC treatment, the difference between
the fracture and no fracture group was 2.4–2.6-fold (Table 2).
Stratifying on initial dose of GC gave slightly higher HR for
DDD < 90 compared with DDD > = 90 for fracture vs. no
fracture group (Table 2).
Age-standardized incidence rates of starting AOD within
1 year after initiating GC showed an increasing trend in the
period 2010–2016 for all studied GC indications (Fig.4).
Adjusting for age and education, the 1-year probability of
receiving AOD, among all women initiating GC, increased
on average 3% per year (HR = 1.03, CI: 1.01, 1.05) from
2010 to 2016. For those with rheumatoid arthritis as indication
for GC treatment, the yearly increase was 3% (HR = 1.03, CI:
1.00, 1.07); for other inflammatory rheumatic diseases, the
increase was 4% (HR = 1.04, CI: 1.01, 1.07), for other indica-
tions 7% (HR = 1.07, CI: 1.02, 1.11), and for no known indi-
cation 3% (HR = 1.05; 1.03, 1.07). Among women with pre-
vious fracture, the increase was 10% per year (HR = 1.10, CI:
1.03, 1.17). There was no significant interaction between
these time trends and type of GC indication or with fracture
status.
Sensitivity analysis
Repeating the analyses reducing the grace period from 180 to
90 days before censoring patients yielded slightly lower HRs
for receiving AOD at 1-year follow-up for women with frac-
ture vs. no fracture (Table 2, 180 days). Cumulative inci-
dences of starting AOD within 1 year increased from 10.1 to
11.6% for rheumatoid arthritis, from 13.1 to 15.4% for other
inflammatory rheumatic diseases, from 3.6 to 5.3% for other
indications, and from 2.4 to 4.2% for indication not known.
The corresponding cumulative incidences at 5-year follow-up




Among postmenopausal women starting GC therapy, those
who had suffered a fracture during the previous 2 years were
twice as likely to start treatment with AOD than women
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Table 1 Baseline characteristics
of Norwegian women (55–
84 years) starting treatment with
glucocorticoids (GC) in the peri-
od 2010–16, stratified by previ-
ous fracture registered in a 2-year
look-back period before starting







Median age (years) at initiation of GC (IQR) 70 (63,77) 67 (61,74)
Age at initiation of GC (N, %)
55–64 years 1116 (28.6) 40,186 (39.6)
65–74 years 1402 (36.0) 37,391 (36.8)
75–84 years 1381 (35.4) 24,001 (23.6)
Year starting GC treatment (N, %)
2010 499 (12.8) 13,672 (13.5)
2011 573 (14.7) 13,901 (13.7)
2012 593 (15.2) 14,901 (14.7)
2013 601 (15.4) 14,637 (14.4)
2014 560 (14.4) 15,176 (14.9)
2015 548 (14.1) 14,926 (14.7)
2016 525 (13.5) 14,365 (14.1)
Number of Defined Daily Doses dispensed of GC at initiation of GC (N, %)
< 90 DDD 3519 (90.3) 92,368 (90.9)
> = 90 DDD 380 (9.7) 9210 (9.1)
Education (N, %)
Basic (compulsory) 1320 (33.9) 32,487 (32.0)
Secondary (high school/vocational) 1877 (48.1) 48,500 (47.7)
Tertiary (college/university) 658 (16.9) 19,429 (19.1)
Unknown/missing 44 (1.1) 1162 (1.1)
CCI score (N, %)
0 2292 (58.8) 71,907 (70.8)
1–2 932 (23.9) 20,279 (20.0)
3+ 675 (17.3) 9392 (9.2)
Comorbidity categoriesa (N, %)
Myocardial infarction 240 (6.2) 3939 (3.9)
Congestive heart failure 187 (4.8) 2005 (2.0)
Peripheral vascular disease 132 (3.4) 2244 (2.2)
Cerebrovascular disease 222 (5.7) 2709 (2.7)
Dementia 68 (1.7) 390 (0.4)
Chronic pulmonary disease 654 (16.8) 9957 (9.8)
Connective tissue disease/inflammatory rheu-
matic diseaseb
217 (5.6) 4567 (4.5)
Rheumatoid arthritis 157 (4.0) 3033 (3.0)
Giant cell arteritis 14 (0.4) 235 (0.2)
Systemic lupus erythematosus 6 (0.2) 220 (0.2)
Dermatopolymyositis 1 (0.0) 56 (0.1)
Polymyalgia rheumatica 43 (1.1) 1088 (1.1)
Systemic sclerosis 6 (0.2) 96 (0.1)
Ulcer disease 59 (1.5) 760 (0.7)
Mild liver disease 33 (0.8) 534 (0.5)
Diabetes 321 (8.2) 5655 (5.6)
Diabetes with end organ damage 141 (3.6) 1884 (1.9)
Hemiplegia 14 (0.4) 127 (0.1)
Moderate or severe renal disease 117 (3.0) 1710 (1.7)
Any tumor, leukemia, lymphoma 454 (11.6) 10,162 (10.0)
Moderate or severe liver disease 18 (0.5) 132 (0.1)








Metastatic solid tumor 121 (3.1) 2262 (2.2)
Other drug use (N, %)
Blood glucose lowering drugs, excluded insulins 306 (7.8) 6982 (6.9)
Hormone replacement therapy 759 (19.5) 25,612 (25.2)
Immunosuppressant drugs 185 (4.7) 3738 (3.7)
Insulin and analogues 149 (3.8) 2326 (2.3)
Proton pump inhibitor 1252 (32.1) 29,001 (28.6)
Reimbursement according to NorPD (ICPC codec or ICD-10 coded) (N, %)
Rheumatoid arthritis 342 (8.8) 8699 (8.6)
Other inflammatory rheumatic disease 269 (6.9) 6543 (6.4)
Other indication 772 (19.8) 17,439 (17.2)
Indication not known 214 (5.5) 4702 (4.6)
Indication according to NPRe (N, %)
Rheumatoid arthritis 32 (0.8) 470 (0.5)
Other inflammatory rheumatic disease 211 (5.4) 2124 (2.1)
Other indication 365 (9.4) 6762 (6.7)
IQR interquartile range,DDDDefined Daily Dose, CCI Romano modification of the Charlson comorbidity index
Women already treated with anti-osteoporotic drugs when starting GC were excluded (5 years look-back)
a According to Charlson comorbidity index (CCI), Romano modification
b Connective tissue disease is the term used in CCI, commonly used term is rheumatic inflammatory diseases
c Reimbursement code associated with first dispensing of GC (primary care). International Classification of
Primary Care (ICPC)
d Reimbursement code associated with first dispensation of GC (specialist health care). International Statistical
Classification of Diseases and Related Health Problems, 10th revision (ICD-10)
e Patient with indication according to the NPR (and no indication in NorPD at first GC dispensing) in the 2-year
baseline period. If more than one relevant diagnosis, the one closest in time before first GC dispensing was chosen
Fig. 2 Cumulative incidence (with 95% confidence bands) of women
starting treatment with anti-osteoporotic drugs (AOD) after initiation of
glucocorticoid (GC) treatment 2010–2016, stratified by having had a
previous fracture or not during the previous 2 past years. The figure to
the left shows data for women with a known chronic disease requiring
long-term treatment (N = 44,028). The figure to the right includes all
women starting GC treatment (N = 105,477)
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without fracture, and this association was strongest among
women with no known indication for GC treatment (HR =
2.6) and in the group “other GC indication” (chronic obstruc-
tive lung disease, asthma, sarcoidosis, dermatitis, and ulcera-
tive colitis) (HR = 2.4). Overall, women with a diagnosis of
inflammatory rheumatic disease were 2–3 times more likely to
start treatment with AOD within the first year compared with
women without this condition. Further, women given an ini-
tial dose of GC of more than 90 DDDwere more than twice as
likely to start AOD treatment within 1 year than women given
less than 90 DDD, both for women with and without previous
fracture. However, the vast majority of women on GC treat-
ment were initially prescribed less than 90 DDD, and a large
proportion of these continued GC treatment beyond 1 year,
Fig. 3 Cumulative incidence (with 95% confidence bands) of women
55–84 years in Norway of starting treatment with anti-osteoporotic drugs
(AOD) after initiation of glucocorticoid (GC) treatment 2010–
2016, stratified by GC indication (left) and by initial Defined Daily
Dose of GC and GC indication (right)
Table 2 Age-standardized incidence rates and risk (HR) of initiating anti-osteoporotic drugs (previous fracture vs. no previous fracture) in 105,477
Norwegian women (55–84 years old) initiating glucocorticoid (GC) treatment in the period 2010–2016
No previous fracture Previous fracture
N/person years Adj. IR1 N/person years Adj. IR1 Adj. HR2 (95% CI)
All women initiating GC 3004/70,264 4.2 (4.1, 4.4) 257/2645 9.0 (7.9, 10.3) 2.0 (1.8, 2.3)
Indication for GC3
Rheumatoid arthritis 788/7245 10.3 (9.5, 11.1) 53/283 16.3 (11.2, 24.4) 1.6 (1.2, 2.1)
Other inflammatory rheumatic disease 981/6471 14.4 (13.5, 15.4) 79/331 21.8 (16.9, 28.0) 1.5 (1.2, 1.9)
Other Indications 491/16,804 2.9 (2.7, 3.2) 59/774 7.8 (5.8, 10.3) 2.4 (1.8, 3.2)
Indication not known 744/39,744 1.9 (1.8, 2.0) 66/1257 5.1 (3.9, 6.6) 2.6 (2.0, 3.4)
Number of Defined Daily Doses dispensed of GC at initiation of GC
< 90 DDD 2208/61,495 3.5 (3.4, 3.7) 198/2297 7.7 (6.6, 9.0) 2.2 (1.9, 2.5)
> = 90 DDD 796/8769 8.9 (8.3, 9.5) 59/347 18.3 (13.7, 24.2) 1.7 (1.3, 2.2)
HR hazard ratio, IR incidence rates, DDD Defined Daily Doses
All women initiating GC by indication for GC use and by number of Defined Daily Doses of GC dispensed at initiation of GC 1-year follow-up
1Age-standardized incidence rates per 100 person years
2 “No previous fracture” as reference. Adjusted for age at initiation of GC, index year, and education
3 Based on reimbursement codes at first GC dispensing (NorPD) or on diagnostics codes (ICD-10) in the 2-year baseline period (NPR)
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which may suggest that AOD treatment should have been
initiated. During the years 2010 to 2016, the rate of AOD
prescribed to those initiating GC increased on average 3%
per year, and this positive trend was higher among women
with (10%) versus without (3%) previous fracture, as well as
among women with other indications for GC treatment (7%),
compared with women with inflammatory rheumatic disease
(3–4%).
Earlier fracture and fracture risk/undertreatment
According to both previous and current guidelines, patients
with previous fractures as well as those receiving GC therapy
formore than 3months are at a high risk for fractures, andAOD
should be considered [10, 12]. The present study found that
women with a recent fracture who initiated GC treatment sub-
sequently started AOD treatment almost twice as often as those
without a previous fracture. Women in the fracture cohort were
older and had more comorbidity than those without recent frac-
tures; thus, the proportion starting AOD should be high.
However, the AOD treatment rates were low, even in this
group. It is worth noticing that among women starting AOD,
the median time from starting GC to prescribing AOD was
more than 1 year, both among those with and without previous
fractures. Low treatment rates in high-risk patients have also
been reported in a Danish study, where only 1/3 of the hip
fracture patients started AOD during the subsequent year [36].
Reimbursement rules have been important for choice of
AOD and decisions concerning whom to treat. In Norway,
osteoporosis confirmed by a BMDmeasurement was required
between 2006 and 2011 , excluding those living in rural areas
without any available device for BMD measurements. In ad-
dition, up to 2012, AOD were only fully reimbursed after a
fracture [15]. Thus, women without a previous fracture or who
did not have a BMD-verified osteoporosis diagnosis had to
pay the full costs for the AOD treatment. This may explain the
low AOD treatment rate in women initiating GC without a
previous fracture. Reimbursement for corticosteroid-induced
osteoporosis was introduced in 2013.
In our nationwide cohort, around 10% of women with a
recent fracture were on AOD after 1 year (incident use) from
GC initiation. In a community study in Central Norway
among women 50–85 years old with a > 20% estimated 10-
year risk of sustaining a major osteoporotic fracture, only 25%
were treated with AOD, further illustrating the level of
undertreatment [37]. There is, however, increased attention
to some risk factors, and long-term use of GC in combination
with sustaining a hip fracture was the strongest predictor for
starting AOD in another Norwegian study [38].
A Canadian study found that women who started taking
GC and who had a previous fracture were more often admitted
to BMD measurements or to receive AOD than those without
a fracture [39]. A French study reported that 26% of women
above 55 years starting GC were treated with osteoporosis
medication, which also included those who only started sup-
plements of calcium and vitamin D [40]. Thus, the proportion
on AOD was even lower.
Inflammatory rheumatic diseases
In our study, women with a diagnosis of an inflammatory
rheumatic disease were more likely to start AOD treatment
within 1 year from GC initiation, compared with women with
other diagnoses, even without having had a recent fracture.
Studies from Norway, the USA, and France have found that
rheumatologists refer patients on GC treatment to BMD mea-
surements and start AOD more frequently than other special-
ists [38, 40, 41]. The American College of Rheumatology
published guidelines for prevention and treatment of GC-
induced osteoporosis as early as in 1996, and the awareness
about inflammation, as well as GC, as a contributing factor to
osteoporosis is high among rheumatologists [42–45].
Equipment for measuring BMD is often allocated to rheuma-
tologic practices, which lowers the threshold for identifying
Fig. 4 Age-standardized
incidence rates with 95%
confidence intervals of starting
with anti-osteoporotic drugs
(AOD) within 1 year after
initiating glucocorticoid (GC)
treatment by type of GC
indication, as a function of year of
initiating GC treatment
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those at risk and starting osteoporosis prophylaxis and treat-
ment. Despite this, a recent French study investigating wheth-
er the guidelines for prevention of GC-induced osteoporosis
were applied in patients with RA found that less than 30% of
those with an indication for treatment received AOD [46].
Guidelines may not be sufficient, and a Japanese group decid-
ed to increase education and attention to GC-induced osteo-
porosis at their hospital by introducing a quality indicator to
monitor prevention and treatment of GC-induced osteoporosis
[47]. They found that these interventions improved the pro-
portion of patients treated with AOD during 2010–2013.
Only a few women with SLE were included in the present
study, and none of these was registered with a fracture. The
incidence of SLE is low in this age group, and thereby few start
GC treatment—thus, most women 55 years and older with SLE
had already started usingGCwhen theywere younger andwere
therefore not eligible for inclusion (i.e. they were not incident
users). In a Spanish study including 576 women with RA or
SLE using long-term GC, 19% had radiologically confirmed
vertebral fracture. The prevalent use of AOD was about 50%
for the total cohort and about 80% for those with a radiologi-
cally confirmed vertebral fracture [48]. This may indicate that
many patients with rheumatic disease on GC start AOD treat-
ment eventually, but preventive treatment may be delayed.
Most patients with PMR/GCA are treated with GC for
several months or years, and AOD would be indicated. The
majority of patients with inflammatory disease other than RA
in our study had PMR/GCA, and this group had the highest
HR for starting AOD treatment (adjusted for age). In a Danish
study, only half of the cohort with PMR/GCA were treated
with AOD even though this is a high-risk population with
median age 73 years and a majority of women [49].
Trends
We found that AOD was increasingly dispensed to women ini-
tiating GC during the years 2010 to 2016, especially from 2013
when bisphosphonates were reimbursed for corticosteroid-
induced osteoporosis. However, this reimbursement was only
for 10 mg alendronate in daily oral administration, not for the
much more frequently prescribed weekly administration. In an
earlier Norwegian study, a decrease in the initiation of AODwas
found during 2004–2007 for a population above 40 years [17]. In
the previously mentioned study fromCentral Norway, the rate of
initiation ofAODafter a forearm fracture did not change between
2005 and 2012 [15]. Our finding is consistent with an increased
awareness of the negative effects of GC on the bone as the AOD
treatment rate increased over time in GC starters. Our finding is
in concordance with the Canadian study reporting a 51% in-
crease in GC-induced osteoporosis preventive care (including
both BMD testing and AOD prescribing) in new users of GC
during the years 1998–2008 [39].
Limitations/strengths
The strength of this study is the nationwide cohort of all
Norwegian women 55–85 years old and the long follow-up
time. We aimed to describe to which degree AOD was dis-
pensed to women initiating GC therapy, thereby focusing
more on the attentiveness of the physicians to anti-
osteoporotic treatment rather than the patients’ adherence to
treatment. As in all studies based on pharmacy-dispensed
medications, the actual number prescribed maybe higher than
the number dispensed, in which case the dispensing rates will
underestimate the actual prescribing rates. Further, we cannot
know whether the medication dispensed was actually taken.
Some information on the use of intravenously administered
bisphosphonates may be lacking, as medications administered
in hospitals and nursing homes are not registered in the
NorPD. Using hospital data on intravenously administered
bisphosphonates (Zoledronic acid) and indication (excluding
cancer diagnosis), both obtained from the NPR, suggests that
the use of AOD is underestimated with about 5%.
We also lack information about treatment with AOD before
the look-back period of 5 year, and some of the patients may
have been on a “drug holiday” after long-term treatment with
AOD and not considered eligible for starting AOD again. The
patient’s motivation is also important for AOD treatment; the
treating physician may have considered AOD and decided not
to start due to comorbidity or patient’s resistance to therapy.
There may be some slight under-reporting of fractures, as only
fractures registered in hospital in- and outpatient clinics and
emergency departments, and not those treated only by the
general practitioner, are included in the Norwegian Patient
Registry.
As 14.5% of those without a fracture in our study
population were on HRT before initiating GC, this may
have been one reason for not starting AOD. HRT has
been found to be a negative predictor for starting AOD
in an earlier study [15].
Bone mineral density data are not available in the national
registry data such as those used in our study, and this repre-
sents a limitation. At the population level, the majority of
women in this age group have either osteoporosis or
osteopenia and should therefore be eligible for osteoporosis
prophylaxis when starting GC treatment had bone mineral
density been measured.
We used 180 days as the allowable treatment gap before
censoring GC patients. Therefore, the number still on GC
treatment and at risk of starting AOD the first year after treat-
ment may be artificially high, compared with if we had used a
smaller treatment gap, such as 90 days. On the other hand,
when using 180 days as the allowable treatment gap, we in-
creased the number at risk 2–4 times, depending on GC indi-
cation and follow-up time, comparedwith using 90 days as the
treatment gap.
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Conclusion
Although postmenopausal women starting long-term GC
treatment are at a high risk of fracture, the majority did
not start treatment with AOD following GC initiation.
The probability of starting AOD was especially low for
women initiating GC with no reported indication for
this treatment. However, we did observe a slight in-
crease in AOD, within 1-year treatment rates, for wom-
en initiating GC from 2010 to 2016 and especially from
2013 when AOD reimbursement for corticosteroid-
induced osteoporosis became available. Women with a
previous fracture or who had an inflammatory rheumatic
disease were more frequently treated with AOD after
initiating GC, but even in these groups the recommen-
dations in guidelines for osteoporosis prophylaxis were
often not followed. The bone harming effect of GC may
not be fully appreciated by physicians, and better rou-
tines for prevention of GC-induced osteoporosis and
fractures should be established. Further, reimbursement
rules should better reflect the international guidelines
not only for osteoporosis treatment but also for
prophylaxis.
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